孟鲁司特钠治疗咳嗽变异性哮喘的临床观察

目的探讨孟鲁司特钠治疗咳嗽变异性哮喘（CVA）的临床疗效。方法42例CVA患者随机分成两组，均以吸入沙丁胺醇气雾剂为基础治疗，在此基础上分别加用孟鲁司特钠（观察组）和布地奈德气雾剂（对照组），比较治疗后两组疗效。结果临床缓解所需时间观察组为（7．1±4．0）d，对照组为（6．3±3．9）d，两组比较差异无统计学意义（P〉0．05）。CVA复发率观察组9．1％，对照组5．0％，两组比较差异无统计学意义（P〉0．05）。结论孟鲁司特钠治疗CVA疗效确切，与吸入激素疗效相当，且副作用少，依从性好，值得临床推广。

Clinical Observation of Montelukast in Treatment of Cough Variant Asthma

Objective To evaluate montelukast sodium in the treatment of cough variant asthma （ CVA ） clinical efficacy. Methods All 42 cases of CVA patients were randomly divided into two groups which were based on inhalation of salbutamol aerosol therapy. On this basis, the addition of montelukast sodium （ observation group ） and budesonide aerosol （ control group ） respectively. Compared the efficacy between two groups after treatment. Results The clinical remission time in the observation group was （7.1 ±4.0 ）d, the control group was （ 6.3 ± 3.9 ） d, the difference was no statistically significant （ P 〉 0.05 ）. CVA recurrence rate of the observation group was 9.1% and the control group was 5.0%, the difference was no statistically significant （P 〉 0.05 ）. Conclusion Montelukast sodium in the treatment efficacy of CVA is as effective as inhaled steroids, and less side effects and good compliance, worthy of promotion.